What is Glaucoma?
- Glaucoma is among the leading causes of blindness in the world
- Glaucoma affects more than 60 million individuals worldwide
Symptoms of Glaucoma
- Unusual trouble adjusting visually to a darkened room
- Difficulty focusing on near or distant objects
- Squinting due to unusually sensitive response to light or glare
- Change in colour of iris
- Recurrent pain in or around eyes
- Double vision
- Dark spot at the center of viewing area
- Excess tearing or “watery eyes”
- Sudden loss of vision in one eye
- Hazy and blurred vision
Causes of Glaucoma
Adult glaucoma has two categories—open angle glaucoma and closed angle glaucoma.
Types of Glaucoma
- Primary Open Angle Glaucoma
- Angle Closure Glaucoma
- Normal Tension Glaucoma (NTG)
- Secondary Glaucoma
- Pediatric Glaucoma
Everyone is at risk for glaucoma, yet there is a group defined for their higher risk potential.
- African-Americans are afflicted with Glaucoma 6-8x more than Caucasians.
- People Over 60 are 6x more likely to get Glaucoma
- Genetics mean that if you have family members with Glaucoma, there is a 4-10x increased risk for developing it
- Older Hispanics
- Asians are at a greater risk for angle closure glaucoma
- Those who use steroids have been studied to have a 40% increase in ocular hypertensions
- Eye injury has the potential to cause a secondary open angle glaucoma
Other Risk Factors.
- high myopia (nearsightedness)
- Central corneal thickness less than .5 mm.
Statistics: Population diagnosed with Glaucoma in Australia
- One in 10 Australians over 80 will develop glaucoma.
- First degree relatives of glaucoma patients have an 8-fold increased risk of developing the disease.
- At present, 50% of people with glaucoma in Australia are undiagnosed.
Medical Cannabis Treatment for Glaucoma
Clinical Studies / Reference
Neuroprotective effect of (-)Delta9-tetrahydrocannabinol and cannabidiol in N-methyl-D-aspartate-induced retinal neurotoxicity: involvement of peroxynitrite.
Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study.